{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:45:29Z","timestamp":1790239529338,"version":"4.1.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"abstract":"<jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>Sepsis causes very high mortality and morbidity rates and remains one of the biggest medical challenges. This study investigates whether plasma levels of both matrix metalloproteinase 8 and tumor necrosis factor receptor 1 are associated with sepsis severity and also investigates the therapeutic applicability of simultaneous inhibition of the two molecules in sepsis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>Observational human pilot study\u2014prospective controlled animal study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Setting:<\/jats:title>\n            <jats:p>University hospital and research laboratory.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Subjects:<\/jats:title>\n            <jats:p>Sepsis patients and C57BL\/6 mice deficient for matrix metalloproteinase 8 and\/or tumor necrosis factor receptor 1.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Intervention:<\/jats:title>\n            <jats:p>Plasma and whole blood RNA were collected from 13 sepsis patients for 7 consecutive days and within 24 hours of admission to ICU. Matrix metalloproteinase 8 and tumor necrosis factor receptor 1 plasma and expression levels were determined in these patients. Mice deficient for both matrix metalloproteinase 8 and tumor necrosis factor receptor 1 were generated and subjected to endotoxemia and cecal ligation and puncture. Additionally, a bispecific Nanobody that simultaneously blocks matrix metalloproteinase 8 and tumor necrosis factor receptor 1 was created.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Measurements and Main Results:<\/jats:title>\n            <jats:p>Plasma levels of matrix metalloproteinase 8 and tumor necrosis factor receptor 1 were positively correlated with the Sequential Organ Failure Assessment score (<jats:italic toggle=\"yes\">r<\/jats:italic>, 0.51 and 0.58) and interleukin 6 levels (<jats:italic toggle=\"yes\">r<\/jats:italic>, 0.59 and 0.52) in 13 sepsis patients. Combined elimination of tumor necrosis factor receptor 1 and matrix metalloproteinase 8 in double knockout mice resulted in superior survival in endotoxemia and CLP compared with single knockouts and wild-type mice. Cotreatment with our bispecific Nanobody in CLP resulted in improved survival rates (28% vs 19%) compared with untreated mice.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Inhibition of matrix metalloproteinase 8 and tumor necrosis factor receptor 1 might have therapeutic potential to treat sepsis and proof-of-principle was provided as therapeutics that inhibit both tumor necrosis factor receptor 1 and matrix metalloproteinase 8 are effective in CLP.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ccm.0000000000002813","type":"journal-article","created":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T21:42:10Z","timestamp":1509572530000},"page":"e67-e75","source":"Crossref","is-referenced-by-count":16,"title":["Simultaneous Inhibition of Tumor Necrosis Factor Receptor 1 and Matrix Metalloproteinase 8 Completely Protects Against Acute Inflammation and Sepsis"],"prefix":"10.1097","volume":"46","author":[{"given":"Sophie","family":"Steeland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Van Ryckeghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien","family":"Vandewalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlies","family":"Ballegeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elien","family":"Van Wonterghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Eggermont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Decruyenaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liesbet","family":"De Bus","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Ghent University Hospital, Ghent, Belgium."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claude","family":"Libert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roosmarijn E.","family":"Vandenbroucke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230728","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"R2-20230728","first-page":"i585","article-title":"Sepsis: Pathophysiology and clinical management.","volume":"353","author":"Gotts","year":"2016","journal-title":"BMJ (Clinical research ed)"},{"key":"R3-20230728","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1164\/rccm.201504-0781OC","article-title":"Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations.","volume":"193","author":"Fleischmann","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"R4-20230728","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1517\/14728214.2016.1132700","article-title":"Emerging drugs for the treatment of sepsis.","volume":"21","author":"Heming","year":"2016","journal-title":"Expert Opin Emerg Drugs"},{"key":"R5-20230728","first-page":"181","article-title":"Management of sepsis.","volume":"74","author":"Schuerholz","year":"2008","journal-title":"Minerva Anestesiol"},{"key":"R6-20230728","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13054-016-1274-9","article-title":"Future of sepsis therapies.","volume":"20","author":"van der Poll","year":"2016","journal-title":"Crit Care"},{"key":"R7-20230728","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/bja\/77.1.110","article-title":"Sepsis and cytokines: Current status.","volume":"77","author":"Blackwell","year":"1996","journal-title":"Br J Anaesth"},{"key":"R8-20230728","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1126\/science.3895437","article-title":"Passive immunization against cachectin\/tumor necrosis factor protects mice from lethal effect of endotoxin.","volume":"229","author":"Beutler","year":"1985","journal-title":"Science"},{"key":"R9-20230728","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1046\/j.1365-3083.1998.00433.x","article-title":"Anti-TNF treatment of baboons with sepsis reduces TNF-alpha, IL-6 and IL-8, but not the degree of complement activation.","volume":"48","author":"Bengtsson","year":"1998","journal-title":"Scand J Immunol"},{"key":"R10-20230728","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00011-013-0683-3","article-title":"Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-\u03b1 (TNF-\u03b1) using AZD9773, an anti-TNF-\u03b1 immune Fab, in murine CLP sepsis.","volume":"63","author":"Newham","year":"2014","journal-title":"Inflamm Res"},{"key":"R11-20230728","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ijcp.12382","article-title":"Anti-TNF-\u03b1 therapy for patients with sepsis: A systematic meta-analysis.","volume":"68","author":"Lv","year":"2014","journal-title":"Int J Clin Pract"},{"key":"R12-20230728","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/sj.bjp.0704549","article-title":"TNF ligands and receptors\u2013a matter of life and death.","volume":"135","author":"MacEwan","year":"2002","journal-title":"Br J Pharmacol"},{"key":"R13-20230728","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cytogfr.2011.09.004","article-title":"Treatment of TNF mediated diseases by selective inhibition of soluble TNF or TNFR1.","volume":"22","author":"Van Hauwermeiren","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"key":"R14-20230728","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0092-8674(93)90134-C","article-title":"Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection.","volume":"73","author":"Pfeffer","year":"1993","journal-title":"Cell"},{"key":"R15-20230728","first-page":"51","article-title":"Phenotypic analysis of TNFR1-deficient mice and characterization of TNFR1-deficient fibroblasts in vitro.","volume":"44","author":"Rothe","year":"1994","journal-title":"Circ Shock"},{"key":"R16-20230728","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/emmm.201202100","article-title":"Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF.","volume":"5","author":"Vandenbroucke","year":"2013","journal-title":"EMBO Mol Med"},{"key":"R17-20230728","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cytogfr.2011.02.002","article-title":"Matrix metalloproteinase8 has a central role in inflammatory disorders and cancer progression.","volume":"22","author":"Dejonckheere","year":"2011","journal-title":"Cytokine Growth Factor Rev"},{"key":"R18-20230728","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nrd4390","article-title":"Is there new hope for therapeutic matrix metalloproteinase inhibition?","volume":"13","author":"Vandenbroucke","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"R19-20230728","doi-asserted-by":"crossref","first-page":"12766","DOI":"10.1523\/JNEUROSCI.0006-15.2015","article-title":"Amyloid \u03b2 oligomers disrupt blood-CSF barrier integrity by activating matrix metalloproteinases.","volume":"35","author":"Brkic","year":"2015","journal-title":"J Neurosci"},{"key":"R20-20230728","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cytogfr.2006.04.001","article-title":"Matrix metalloproteinase-8: Cleavage can be decisive.","volume":"17","author":"Van Lint","year":"2006","journal-title":"Cytokine Growth Factor Rev"},{"key":"R21-20230728","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nrd2308","article-title":"Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.","volume":"6","author":"Hu","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"R22-20230728","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/CCM.0b013e31823b97d7","article-title":"Matrix metalloproteinase-8 as a potential drug target for the therapy of sepsis.","volume":"40","author":"Fink","year":"2012","journal-title":"Crit Care Med"},{"key":"R23-20230728","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/CCM.0b013e318232e404","article-title":"A novel role for matrix metalloproteinase-8 in sepsis.","volume":"40","author":"Solan","year":"2012","journal-title":"Crit Care Med"},{"key":"R24-20230728","doi-asserted-by":"crossref","first-page":"5002","DOI":"10.1038\/srep05002","article-title":"Role of plasma matrix-metalloproteases (MMPs) and their polymorphisms (SNPs) in sepsis development and outcome in ICU patients.","volume":"4","author":"Martin","year":"2014","journal-title":"Sci Rep"},{"key":"R25-20230728","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jcrc.2011.01.008","article-title":"Elevated plasma matrix metalloproteinases and their tissue inhibitors in patients with severe sepsis.","volume":"26","author":"Yazdan-Ashoori","year":"2011","journal-title":"J Crit Care"},{"key":"R26-20230728","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.phrs.2011.06.019","article-title":"Serum MMP-8, -9 and TIMP-1 in sepsis: High serum levels of MMP-8 and TIMP-1 are associated with fatal outcome in a multicentre, prospective cohort study. Hypothetical impact of tetracyclines.","volume":"64","author":"Lauhio","year":"2011","journal-title":"Pharmacol Res"},{"key":"R28-20230728","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.bcp.2005.04.047","article-title":"Targeting neutrophil collagenase\/matrix metalloproteinase-8 and gelatinase B\/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock.","volume":"70","author":"Hu","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"R29-20230728","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/mt.2016.2","article-title":"Development and validation of a small single-domain antibody that effectively inhibits matrix metalloproteinase 8.","volume":"24","author":"Demeestere","year":"2016","journal-title":"Mol Ther"},{"key":"R30-20230728","doi-asserted-by":"crossref","first-page":"9805","DOI":"10.1523\/JNEUROSCI.0967-12.2012","article-title":"Matrix metalloprotease 8-dependent extracellular matrix cleavage at the blood-CSF barrier contributes to lethality during systemic inflammatory diseases.","volume":"32","author":"Vandenbroucke","year":"2012","journal-title":"J Neurosci"},{"key":"R31-20230728","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1021\/acs.jmedchem.7b00018","article-title":"Second generation triple-helical peptide inhibitors of matrix metalloproteinases.","volume":"60","author":"Bhowmick","year":"2017","journal-title":"J Med Chem"},{"key":"R32-20230728","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.4049\/jimmunol.1303240","article-title":"Matrix metalloproteinase-8 plays a pivotal role in neuroinflammation by modulating TNF-\u03b1 activation.","volume":"193","author":"Lee","year":"2014","journal-title":"J Immunol"},{"key":"R33-20230728","doi-asserted-by":"crossref","first-page":"7642","DOI":"10.4049\/jimmunol.175.11.7642","article-title":"Resistance of collagenase-2 (matrix metalloproteinase-8)-deficient mice to TNF-induced lethal hepatitis.","volume":"175","author":"Van Lint","year":"2005","journal-title":"J Immunol"},{"key":"R34-20230728","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-4804(80)90037-2","article-title":"Sepsis and septic shock\u2013a review of laboratory models and a proposal.","volume":"29","author":"Wichterman","year":"1980","journal-title":"J Surg Res"},{"key":"R35-20230728","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1074\/jbc.M114.617787","article-title":"Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1.","volume":"290","author":"Steeland","year":"2015","journal-title":"J Biol Chem"},{"key":"R37-20230728","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/0885066610384465","article-title":"Mortality in patients with septic shock correlates with anti-inflammatory but not proinflammatory immunomodulatory molecules.","volume":"26","author":"de Pablo","year":"2011","journal-title":"J Intensive Care Med"},{"key":"R38-20230728","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/SHK.0000000000000616","article-title":"Interleukin-6 levels act as a diagnostic marker for infection and a prognostic marker in patients with organ dysfunction in intensive care units.","volume":"46","author":"Takahashi","year":"2016","journal-title":"Shock"},{"key":"R39-20230728","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine.","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"R40-20230728","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tim.2011.01.001","article-title":"Cecal ligation and puncture: The gold standard model for polymicrobial sepsis?","volume":"19","author":"Dejager","year":"2011","journal-title":"Trends Microbiol"},{"key":"R41-20230728","doi-asserted-by":"crossref","first-page":"13646","DOI":"10.1038\/s41598-017-13984-y","article-title":"TNFR1 inhibition with a Nanobody protects against EAE development in mice.","volume":"7","author":"Steeland","year":"2017","journal-title":"Sci Rep"},{"key":"R42-20230728","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.molmed.2014.01.007","article-title":"Why have clinical trials in sepsis failed?","volume":"20","author":"Marshall","year":"2014","journal-title":"Trends Mol Med"},{"key":"R43-20230728","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/nature03985","article-title":"A network-based analysis of systemic inflammation in humans.","volume":"437","author":"Calvano","year":"2005","journal-title":"Nature"},{"key":"R44-20230728","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1164\/rccm.201308-1535OC","article-title":"Simultaneous targeting of IL-1 and IL-18 is required for protection against inflammatory and septic shock.","volume":"189","author":"Vanden Berghe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"R45-20230728","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00003246-200103000-00001","article-title":"Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality.","volume":"29","author":"Remick","year":"2001","journal-title":"Crit Care Med"},{"key":"R46-20230728","doi-asserted-by":"crossref","first-page":"165974","DOI":"10.1155\/2013\/165974","article-title":"Cytokines in sepsis: Potent immunoregulators and potential therapeutic targets\u2013an updated view.","volume":"2013","author":"Schulte","year":"2013","journal-title":"Mediators Inflamm"},{"key":"R47-20230728","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3109\/00365548.2011.600325","article-title":"Early detection of severe sepsis in the emergency room: Diagnostic value of plasma C-reactive protein, procalcitonin, and interleukin-6.","volume":"43","author":"Uusitalo-Sepp\u00e4l\u00e4","year":"2011","journal-title":"Scand J Infect Dis"},{"key":"R48-20230728","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/01.shk.0000157301.87051.77","article-title":"Opposing effects of tumor necrosis factor receptor 1 and 2 in sepsis due to cecal ligation and puncture.","volume":"23","author":"Ebach","year":"2005","journal-title":"Shock"},{"key":"R49-20230728","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.immuni.2015.06.011","article-title":"Passenger mutations confound interpretation of all genetically modified congenic mice.","volume":"43","author":"Vanden Berghe","year":"2015","journal-title":"Immunity"},{"key":"R50-20230728","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1084\/jem.20160027","article-title":"Complement pathway amplifies caspase-11-dependent cell death and endotoxin-induced sepsis severity.","volume":"213","author":"Napier","year":"2016","journal-title":"J Exp Med"},{"key":"R51-20230728","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2017.36","article-title":"The immunopathology of sepsis and potential therapeutic targets.","volume":"17","author":"van der Poll","year":"2017","journal-title":"Nat Rev Immunol"}],"container-title":["Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003246-201801000-00042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T07:08:18Z","timestamp":1690528098000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003246-201801000-00042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/ccm.0000000000002813","relation":{},"ISSN":["0090-3493"],"issn-type":[{"value":"0090-3493","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}